Targeted Radiation Delivery Before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-Term Survivors.

Johnnie J Orozco Phuong T Vo Theodore A Gooley Robyn L Haaf Sally J Lundberg Donald K Hamlinn D Scott Wilbur Manuela C Matesan Darrell R Fisher Ajay K Gopal Damian J Green John M Pagel Brenda M Sandmaier

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

131l-anti-CD45 radioimmunotherapy prior to haploidentical HCT is feasible and can be curative in some patients, including those with disease, without additional toxicity.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
bone marrow
peritoneal dialysis
acute myeloid leukemia
oxidative stress
cell proliferation
drug delivery
rectal cancer
cord blood
cancer therapy